Importantly, these interim results also met the FDA primary endpoint
-sustained clinical recovery,
the resolution of symptoms and
prevented the need for intensive care or invasive mechanical ventilation.
This is in accordance with FDA guidelines on the inclusion criteria
for the treatment of high-risk, COVID-19 infected patients
Phase II clinical trial is currently underway
Currently there are a further 19 patients undergoing this Phase IIa trial, with a maximum number of 50.
- Forums
- ASX - By Stock
- RGT
- Ann: COVID-19 Interim Trial Results Meet All Primary Objectives
Ann: COVID-19 Interim Trial Results Meet All Primary Objectives, page-65
-
- There are more pages in this discussion • 77 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RGT (ASX) to my watchlist
|
|||||
Last
35.0¢ |
Change
0.015(4.48%) |
Mkt cap ! $16.94M |
Open | High | Low | Value | Volume |
34.5¢ | 35.5¢ | 33.0¢ | $60.95K | 174.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 11855 | 27.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.0¢ | 1338 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 11855 | 0.270 |
1 | 20000 | 0.250 |
1 | 2200 | 0.230 |
1 | 14600 | 0.205 |
2 | 17358 | 0.165 |
Price($) | Vol. | No. |
---|---|---|
0.390 | 14 | 1 |
0.400 | 6621 | 3 |
0.415 | 225 | 1 |
0.420 | 147 | 2 |
0.430 | 28 | 1 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
RGT (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online